Premium
Severe progressive scarring pembrolizumab‐induced lichen planopilaris in a patient with metastatic melanoma
Author(s) -
Uthayakumar Aarthy K,
Rudd Emily,
Noy Mariana,
Weir Justin,
Larkin James,
Fearfield Louise
Publication year - 2021
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.13660
Subject(s) - medicine , pembrolizumab , dermatology , adverse effect , metastatic melanoma , immunotherapy , quality of life (healthcare) , melanoma , lichen sclerosus , oncology , cancer , cancer research , nursing
ABSTRACT Lichenoid reactions are one of the many cutaneous immune‐related adverse events seen with the use of immune checkpoint inhibitors, particularly anti‐PD1 inhibitors. We present a rare care of severe lichen planopilaris secondary to pembrolizumab, with progression even after cessation of immunotherapy. It is important to recognise the significant long‐term impact of these cutaneous adverse effects on patient’s quality of life.